Immunome, Inc.IMNMNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank14
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P14
Within normal range
vs 2Y Ago
-1x
Contraction
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
2025-72.32%
2024-1363.98%
202373.62%
2022-57.41%
2021-50.21%
2020-26.40%
2019-29.62%
20180.00%